Trial Profile
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2023
Price :
$35
*
At a glance
- Drugs ETC 1922159 (Primary) ; Pembrolizumab (Primary) ; Denosumab
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- 07 Nov 2023 Planned End Date changed from 1 Aug 2024 to 1 May 2024.
- 07 Nov 2023 Planned primary completion date changed from 1 Dec 2020 to 1 Feb 2024.
- 07 Nov 2023 Status changed from recruiting to active, no longer recruiting.